AU2020367905A1 - The salts of a compound and the crystalline forms thereof - Google Patents

The salts of a compound and the crystalline forms thereof Download PDF

Info

Publication number
AU2020367905A1
AU2020367905A1 AU2020367905A AU2020367905A AU2020367905A1 AU 2020367905 A1 AU2020367905 A1 AU 2020367905A1 AU 2020367905 A AU2020367905 A AU 2020367905A AU 2020367905 A AU2020367905 A AU 2020367905A AU 2020367905 A1 AU2020367905 A1 AU 2020367905A1
Authority
AU
Australia
Prior art keywords
cancer
salt
iii
formula
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020367905A
Other languages
English (en)
Inventor
Ling Feng
Wenji Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Ltd
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of AU2020367905A1 publication Critical patent/AU2020367905A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020367905A 2019-10-14 2020-10-13 The salts of a compound and the crystalline forms thereof Pending AU2020367905A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910973785.3 2019-10-14
CN201910973785 2019-10-14
PCT/CN2020/120594 WO2021073494A1 (en) 2019-10-14 2020-10-13 The salts of a compound and the crystalline forms thereof

Publications (1)

Publication Number Publication Date
AU2020367905A1 true AU2020367905A1 (en) 2022-04-21

Family

ID=75537486

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020367905A Pending AU2020367905A1 (en) 2019-10-14 2020-10-13 The salts of a compound and the crystalline forms thereof

Country Status (14)

Country Link
US (2) US12559472B2 (cg-RX-API-DMAC7.html)
EP (1) EP4045484A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022552329A (cg-RX-API-DMAC7.html)
KR (1) KR20220088712A (cg-RX-API-DMAC7.html)
CN (3) CN119751422A (cg-RX-API-DMAC7.html)
AR (1) AR120202A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020367905A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007035A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154064A1 (cg-RX-API-DMAC7.html)
IL (1) IL292206B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022004274A (cg-RX-API-DMAC7.html)
TW (1) TWI895290B (cg-RX-API-DMAC7.html)
UA (1) UA129777C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021073494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4450499A4 (en) * 2021-12-13 2025-12-17 Abbisko Therapeutics Co Ltd FGFR4-inhibitoric acid salt, manufacturing process and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
US20160052926A1 (en) * 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
CN107660200B (zh) * 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
CN110023318A (zh) * 2016-12-01 2019-07-16 和记黄埔医药(上海)有限公司 化合物的晶型

Also Published As

Publication number Publication date
TWI895290B (zh) 2025-09-01
CN114555558B (zh) 2024-12-17
CN114555558A (zh) 2022-05-27
BR112022007035A2 (pt) 2022-06-28
EP4045484A1 (en) 2022-08-24
WO2021073494A1 (en) 2021-04-22
IL292206B2 (en) 2026-03-01
US20230121346A1 (en) 2023-04-20
CA3154064A1 (en) 2021-04-22
EP4045484A4 (en) 2023-09-06
JP2025143319A (ja) 2025-10-01
US20260138967A1 (en) 2026-05-21
IL292206B1 (en) 2025-11-01
UA129777C2 (uk) 2025-07-30
US12559472B2 (en) 2026-02-24
CN119751422A (zh) 2025-04-04
CN119462616A (zh) 2025-02-18
IL292206A (en) 2022-06-01
MX2022004274A (es) 2022-05-06
TW202128669A (zh) 2021-08-01
JP2022552329A (ja) 2022-12-15
KR20220088712A (ko) 2022-06-28
AR120202A1 (es) 2022-02-02

Similar Documents

Publication Publication Date Title
CN119654319A (zh) 一种cdk抑制剂及其磷酸盐的多晶型
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
US12600713B2 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
KR20170032330A (ko) C-Met 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
TW201236684A (en) Pharmaceutically acceptable salts of (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation process and pharmaceutical use there of
US20260138967A1 (en) The salts of a compound and the crystalline forms thereof
EP2504331B1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
EP4399207B1 (en) Crystalline forms of quinazoline derivatives, preparation, composition and use thereof
CN109593102A (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
CN110256408B (zh) 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
WO2026026904A1 (en) The crystalline forms of a compound
EA046831B1 (ru) Соли соединения и их кристаллические формы
HK40120202A (en) The salts of a compound and the crystalline forms thereof
HK40122795A (en) The salts of a compound and the crystalline forms thereof
TWI867817B (zh) 一種二噁烷並喹啉類化合物的鹽、其晶型以及它們的製備方法及用途
CN111892536A (zh) 取代的喹啉甲酰胺类化合物及其用途
HK40068973A (en) The salts of a compound and the crystalline forms thereof
HK40068973B (en) The salts of a compound and the crystalline forms thereof
AU2022411531B2 (en) Fgfr4 inhibitor acid salt, preparation method therefor, and use thereof
WO2022247772A1 (zh) 一种含氧杂环化合物的晶型、其制备方法及应用
HK40019691A (en) The salts of a compound and the crystalline forms thereof
HK40024929B (en) Crystalline forms of a compound
CN104557955A (zh) 作为PI3K/mTOR抑制剂的三环类化合物,其制备方法和用途